Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 11, 2018Journal of the Endocrine SocietyOpen Access

The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening

View Full Paper
Ask AI
Bookmark
Share

Population

A 52-year-old woman with a 25-year history of macroprolactinoma

Design

Case_report

Key result

Routine cardiovascular examination detected a new murmur leading to the diagnosis of cabergoline-associated valvulopathy in a 52-year-old woman after a cumulative cabergoline dose of 4192 mg.

Authors

CCCarmela CaputoDPDavid PriorWIWarrick J. Inder

Discussion

Loading...

Member takes

Overview

in patients on high-dose dopamine agonists.

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
A 52-year-old woman with a 25-year history of macroprolactinoma who developed cabergoline-associated valvulopathy.
E
Exposure
Routine cardiovascular examination and cabergoline therapy (6 mg weekly, cumulative dose 4192 mg)
O
Outcome
Detection of cabergoline-associated valvulopathy (CAV)safety

Routine annual cardiovascular examination is a valuable screening tool for detecting cabergoline-associated valvulopathy in patients with prolactinoma.

Cite This Study

Caputo et al. (2018) conducted a case report in Macroprolactinoma (n=1). Cabergoline was evaluated on Cabergoline-associated valvulopathy. Routine cardiovascular examination detected a new murmur leading to the diagnosis of cabergoline-associated valvulopathy in a 52-year-old woman after a cumulative cabergoline dose of 4192 mg.

synapsesocial.com/papers/6aa413ae5b75cc9dd9c9790fhttps://doi.org/10.1210/js.2018-00139
View Full Paper
Ask AI
Bookmark
Share